secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001558370-23-009981
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ReShape Lifesciences Q1 2023 revenue down 6.3% to $2.3M; operating expenses cut 42.9% YoY
--------------------------------------------------------------------------------

- Revenue $2.3M (down 6.3% YoY); gross margin improved to 53.5% from 49.9%.
- Sales & marketing expenses fell 53.5% to $2.2M; R&D down 39.2% to $0.5M.
- Cash $9.1M at March 31, 2023; no debt; expects runway into 2024.
- Raised $12.7M in 2023 via February public offering ($10.2M) and April direct offering ($2.5M).
- Lap-Band 2.0 PMA supplement submission to FDA expected in coming weeks; feedback by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000155837023009981/0001558370-23-009981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000155837023009981/rsls-20230515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer